Columbia University Medical Center-Herbert Irving Pavilion

New York, New York 10032

4 studies enrolling now · 22 studies all time

What they study most

Acute Myeloid Leukemia, Advanced/Metastatic Solid Tumors or Lymphomas, Astrocytoma, Astrocytoma, IDH-Mutant, Basal Cell Carcinoma, Bladder Cancer, Breast Carcinoma, Burkitt's Lymphoma, CML, Carcinoma, Renal Cell, Castration-Resistant Prostate Carcinoma, Cervical Cancer

Studies at this site

• Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer — Recruiting now
• A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer — Recruiting now
• A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors — Recruiting now
• Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions — Recruiting now
• Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma — Recruiting now
• Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) — Running, not enrolling
• A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer — Running, not enrolling
• Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell Disease — Completed
• Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion — Running, not enrolling
• Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031 — Stopped early
• 177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer — Running, not enrolling
• Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated — Stopped early
• Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) — Stopped early
• A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC) — Completed
• PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) — Withdrawn before enrolling
• A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors — Completed
• Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 — Completed
• Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine — Completed
• Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas — Stopped early
• Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) — Completed
• Efficacy Study Of Tofacitinib In Pediatric JIA Population — Completed
• A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation — Completed